Table 1 Clinicopathologic characteristics of all patients with metastatic endometrial carcinoma treated with neoadjuvant chemotherapy
Characteristics | Total (n = 32, %) |
|---|---|
Age at diagnosis, years | |
Median (range) | 56 (34–77) |
Menopausal status | |
Premenopause | 9 (28.1) |
Postmenopause | 23 (71.9) |
Histologic subtype | |
Endometrioid | 18 (56.3) |
Serous | 5 (15.6) |
Clear cell | 1 (3.1) |
Carcinosarcoma | 6 (18.8) |
Others | 2 (6.3) |
Grade | |
Low | 11 (34.3) |
High | 7 (21.9) |
Not applicable | 14 (43.8) |
FIGO stage | |
IIIC | 4 (12.5) |
IVB | 28 (87.5) |
CA-125 at diagnosis, IU/ml | |
Median (range) | 192.7 (8.6–3489.0) |
CA-125 after NAC, IU/ml | |
Median (range) | 20.2 (7.0–1490.0) |
NAC regimen | |
Paclitaxel-carboplatin | 25 (78.1) |
Doxorubicin-cisplatin | 2 (6.3) |
Paclitaxel-cisplatin-bevacizumab | 2 (6.3) |
Ifosfamide-cisplatin | 2 (6.3) |
Etoposide-cisplatin | 1 (3.1) |
Number of NAC cycles | |
Median (range) | 6 (2–12) |
2–3 | 11 (34.4) |
4–6 | 10 (31.2) |
≥7 | 11 (34.4) |
Response to NAC | |
CR | 2 (6.3) |
PR | 24 (75.0) |
SD | 4 (12.5) |
PD | 2 (6.3) |
Residual tumor after IDS | |
No gross residual | 23 (71.9) |
< 1 cm | 7 (21.9) |
≥ 1 cm | 2 (6.2) |